The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
May 16 (Reuters) - (This May 16 story has been officially corrected by Amgen to change the pricing estimate in paragraph 4) The U.S. Food and Drug Administration on Thursday granted accelerated ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
El jueves, la FDA aprobó el Imdelltra (tarlatamab-dlle) de Amgen Inc (NASDAQ:AMGN) para el tratamiento de pacientes adultos con cáncer de pulmón microcítico de células pequeñas en estadio ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen’s tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
El jueves, la FDA aprobó el Imdelltra (tarlatamab-dlle) de Amgen Inc (NASDAQ:AMGN) para el tratamiento de pacientes adultos con ...
FRIDAY, May, 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
AbbVie ABBV dosed the first patient with ABBV-383, an investigational BCMA-CD3-targeted bispecific antibody, in the phase III ...